Twist Bioscience (TWST) +69.6% in 30 Days: AI Drug Discovery Fuels Momentum
Key Takeaways
- TWST shares have climbed roughly 69.6% over the last 30 days, rising from a July 28 closing level near $88.55 to approximately $150 as of late August.
- The rally was powered by a strong fiscal Q3 2026 report, which delivered record revenue, a guidance raise, and a clearer path to adjusted EBITDA breakeven.
- AI-enabled drug discovery has emerged as the company's central growth narrative, with management guiding to triple-digit order growth in fiscal 2026 and again in fiscal 2027.
- Over the last quarter the stock has more than doubled, extending a multi-month uptrend that has made TWST one of the more volatile, higher-momentum names in synthetic biology.
- Key risks remain: ongoing net losses, customer concentration, and a premium valuation that leaves limited margin for execution missteps.
Twist Bioscience's Place in Synthetic Biology
Twist Bioscience Corporation is a synthetic biology company headquartered in South San Francisco, California. The company has pioneered a proprietary silicon-based DNA synthesis platform that applies semiconductor manufacturing techniques to produce synthetic genes, oligonucleotides, and gene fragments at scale. This approach allows Twist to synthesize DNA more quickly and at lower cost than traditional chemical methods.
Twist operates two core reporting segments: DNA Synthesis and Protein Solutions (DSPS) and NGS Applications. Its products support drug discovery, antibody engineering, diagnostics, industrial biotechnology, agriculture, and academic research. Increasingly, the company is positioning itself as infrastructure for AI-driven drug discovery, where customers use machine-learning models to generate large numbers of candidate DNA sequences that Twist synthesizes and characterizes. I follow TWST closely because of its exposure to the convergence of artificial intelligence and life sciences, its recurring revenue characteristics, and its progress toward profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, TWST has advanced approximately 69.6%. The stock closed near $88.55 on July 28 and traded around $150 by late August, a gain driven primarily by the company's fiscal third-quarter earnings release and the sustained AI-enabled drug discovery narrative that followed.
The move is even more pronounced when viewed over a full quarter. Roughly three months earlier, in late May, TWST traded near $67. The shares have since risen about 125%, meaning the stock has more than doubled over the quarter. The current advance represents the latest leg of a longer uptrend: TWST has been among the strongest performers in the genomics and synthetic biology space, with the rally accelerating after earnings and building through August. The stock's elevated beta and rapid price swings underscore both strong investor enthusiasm and meaningful volatility.
What Powered the 30-Day Advance
The single most important catalyst in the 30-day window was Twist's fiscal Q3 2026 earnings report, released August 3. The company posted record revenue of $118.4 million, up 23% year over year and its 14th consecutive quarter of sequential growth. Gross margin improved to 52.8%, and management raised full-year fiscal 2026 revenue guidance to $456 million to $457 million, implying roughly 21% growth at the midpoint.
Investors focused most heavily on the AI-enabled drug discovery opportunity. Management reiterated confidence in meeting or exceeding triple-digit percentage order growth for AI-enabled discovery in fiscal 2026 and indicated it could repeat that performance in fiscal 2027. During the earnings call, the CFO framed the trajectory from roughly $25 million in AI-related orders in fiscal 2025 toward $50 million in fiscal 2026 and $100 million in fiscal 2027. Therapeutics revenue, a key beneficiary of this trend, rose 49% year over year to $40.4 million.
The company also reaffirmed its expectation to reach adjusted EBITDA breakeven in the fiscal fourth quarter, an important profitability milestone for a company still reporting net losses. Additional drivers included the commercial launch of Twist's Complex Genes offering, continued growth in DNA Synthesis and Protein Solutions (up 39% year over year), and broader investor appetite for AI-adjacent life sciences assets. Despite a brief premarket dip when the earnings report first crossed the wires, shares reversed sharply higher during the session and continued to climb through August.
Factors Behind the Quarterly Gains
The quarterly surge reflects a broader repricing of Twist's role in the AI-enabled drug discovery ecosystem. In May, the company hosted an Investor Day at its Wilsonville, Oregon facility, where it outlined triple-digit order growth expectations and framed AI-driven discovery as a durable, recurring growth engine rather than a one-off trend. That message, reinforced by the August earnings report, helped sustain buying throughout the period.
The quarter also demonstrated the platform's real-world utility. Twist's Comprehensive Viral Research Panel was used by researchers in the Democratic Republic of the Congo to identify a rare strain of Ebola that standard PCR testing missed, and the company synthesized hantavirus material in under 24 hours during a separate public health response. These events highlighted the breadth and speed of the platform. Institutional activity has also been notable, with several large asset managers adding to positions in recent quarters, while a steady pattern of insider sales has persisted as shares have appreciated. The combination of a compelling AI narrative, accelerating revenue growth, improving gross margins, and a concrete path to breakeven has driven the stock's multi-month re-rating. From what I see, patterns confirmed via Tickeron’s AI Pattern Search Engine align with the ongoing momentum.
What to Watch Next for TWST
Several factors are likely to shape TWST's trajectory in the months ahead. First, the company has guided to adjusted EBITDA breakeven in its fiscal fourth quarter, and the actual result will be closely scrutinized as a test of whether revenue growth can translate into profitability. Management has also said it will provide full fiscal 2027 guidance in November, which will clarify whether the strong growth momentum is expected to continue.
Investors should monitor the pace of AI-enabled drug discovery orders and the conversion of those orders into recognized revenue, as well as gross margin progression toward the company's longer-term target of above 60%. Other watchpoints include customer concentration in the NGS segment, where the top 10 accounts represent a meaningful share of revenue, competitive dynamics in synthetic biology, and broader sentiment toward high-valuation, high-growth biotechnology names. As always, quarterly results, guidance updates, and any changes to the company's profitability timeline will be key drivers of near-term price action.
Exploring AI Tools for Market Context
When analyzing momentum names like TWST, I find it useful to review Tickeron's Trending AI Robots for additional perspective on how AI-driven systems are interpreting technical signals and market trends. The page highlights top-performing bots across strategies and timeframes, offering a practical way to cross-check my own observations without replacing independent analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TWST's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for TWST turned positive on September 17, 2026. Looking at past instances where TWST's MACD turned positive, the stock continued to rise in 42 of 45 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on TWST as a result. In 69 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
Following a +16.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 234 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 184 of 232 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.814) is normal, around the industry mean (25.951). P/E Ratio (0.000) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (436.793).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology
Advertisement